EXECUTIVE INTERVIEWS

• From Biggest Pharma To Rare Disease Start-Up

  Martin Mackay’s journey from Pfizer executive to founding and leading a rare disease biotech is a reflection of the industry’s evolution from a small molecule powerhouse to multimodal biotech. 

• Leading Aulos Bioscience’s “Triumvirate” Model

  Aulos Bioscience hopes to leverage its unique business model, engineered by a VC firm and an Israeli biotech, to develop better treatments for solid tumors.

• The Skin Is The Game: New Ways To Play In Dermatology

  As the established indications in dermatology become saturated with competing products, a variety of companies, from start-ups to oncology players, are finding opportunities in underserved indications and reformulated drugs.

• Fortress Biotech’s Network Flex Business Model

  Fortress Biotech CEO Lindsay Rosenwald talks up Fortress Biotech’s business model, which leverages partner companies to develop promising but underexposed drug candidates.

• Hitting The Ground Running In Oncology

  David Lee, CEO at Servier Pharmaceuticals, talks about how he set up the French company’s U.S. division, and his goal of reaching $2 billion in annual oncology product revenue.

• U.S. Patent Expired? Why Not Grow Revenue Globally, Says Amarin

  Amarin is deploying a global strategy to expand patient access to Vascepa, hoping to make up for lost revenues in the U.S.

• Gene Therapy Developer Rocket Pharma Aims High

  “From our first patient until now, all our manufactured drug product that has treated patients has been produced in partnership with CDMOs,” says Gaurav Shah, M.D., cofounder and CEO of Rocket Pharma.

• Making The Right Deal For Biohaven

  Biohaven CEO Vlad Coric describes the events leading up to Pfizer’s $11.6 billion acquisition, his drug launch during the start of COVID-19, and why company titles and seniority don’t really matter.

• Translating Nobel Prize Winning Science Into Medicine

  2022 Nobel Prize winner Carolyn Bertozzi discusses her approach to translating scientific discoveries into biopharmaceutical products, and her ongoing partnership with Shasqi CEO José Mejía Oneto.

• Why Takeda Is Focusing So Much On Plasma-Derived Therapies

  Tasked with driving future growth of Takeda’s plasma-derived therapies, Giles Platford, business unit president, shares his approach to partnering, promoting market access, and improving patient experiences.

• With Fundraising, A Track Record Matters: GeoVax’s David Dodd

  Industry veteran David Dodd, chairman and CEO at GeoVax, answers questions about the fundraising environment for small biotechs, and the dangers of toxic warrants.

• Verve Therapeutics: How To Build A Gene Editing Biotech

  Verve Therapeutics’ co-founder and CEO Sekar Kathiresan offers insight into how he launched a gene editing drug company and dosed the first patient in less than four years.

• Executive Outlook: Crafting New Solutions For Persisting Problems

  Creativity will be in high demand, not just to control costs during tough economic conditions, but in key functional areas like business development and external collaboration, ESG (environmental, social, and governance), and diversity, equity and inclusion (DE&I).

• A More Balanced And Stable Future With CDMOs

  Two Industry Experts talk about where they see the outsourcing industry going in the near future.